This award validates that our novel inhaled therapies “ which have the unique ability to treat and prevent a broad range of infections from different airborne viruses, bacteria or bugs ™ “ represent a promising approach to address respiratory diseases in a fundamentally new way. Pulmatrix ™s technology is attractive because of its unique ability to enhance the airway and lungs own natural biophysical properties and host defense mechanisms, in a pathogen-independent manner. Thus, single product formulations may have the ability to address multiple infectious agents, including different strains of influenza as well as a wide range of other respiratory diseases, said Robert Connelly, Chief Executive Officer of Pulmatrix. Pulmatrix has made significant progress with our product pipeline, including ongoing and planned clinical trials in influenza and other respiratory diseases.

SOURCE Pulmatrix